

RESEARCH ARTICLE

CHRONIC RESPIRATORY DISEASES MANAGEMENT DURING AND BEYOND COVID 19 PANDEMIC: A REVIEW ON CHANGES AND CHALLENGES

Cahayag K., Geronan M.G, Geronan G.J and Sebastian A.

School of Allied Health Sciences, Respiratory Therapy, San Pedro College, Davao City, Philippines, 8000.

Manuscript Info

Abstract

Manuscript History Received: 28 February 2023 Final Accepted: 31 March 2023 Published: April 2023

Key words:-

Chronic Respiratory Diseases, Chronic Diseases Management, Covid 19 Pandemic, Chronic Respiratory Diseases Management During Covid 19, Chronic Respiratory Diseases Management Beyond Covid 19; Management, Treatment

..... The COVID-19 pandemic has been a challenge to healthcare systems around the world, not only because of the disease's severity and high fatality rate, but also because of the effects on the treatment of people with chronic illnesses^[3]. The COVID-19 pandemic had caused effects on the treatment of people with chronic respiratory illnesses. This brought a great challenge to the healthcare systems around the world. The pandemic had a significant impact on routine medical activities by restricting access to specific diagnosis procedures, necessitating the creation of new techniques for illness monitoring, and requiring the adaptation of therapeutic approaches ^[4]. The health care system abruptly changed its care management strategy during the pandemic to a completely virtual, remote model, and the team continued to offer transitional care assistance for hospitalized patients to prevent the usual mistakes that are linked to bad results ^[12]. Therefore, this aims to review the changes and challenges in treating people with chronic respiratory illnesses during and beyond the Covid-19 pandemic.

Copy Right, IJAR, 2023,. All rights reserved.

.....

Introduction:-Methods:-

This journal review assessed the different changes and challenges in treating people with chronic respiratory illnesses through the analysis and research of related topics, journal articles, and research. Related literature was taken from published articles and journal reviews on the following websites: 1. Google Scholar 2. National Library of Medicine 3. PubMed 4. ACP Journals 5. and other credible supplementing websites that showcased relevant concepts about the topic.

Literature Search:-

Author and Year	Title	Results/Outcome	Country/
			Origin
Tiotiu, A., Chong Neto, H., Bikov, A., Kowal, K.,	Impact of the	The pandemic highly	France,
Steiropoulos, P., Labor, M., Cherrez-Ojeda, I.,	COVID-19	impacted our usual medical	Brazil,
Badellino, H., Emelyanov, A., Garcia, R., &	pandemic on the	activities by limiting the	Greece,
Guidos, G. (2021)	management of	access to several diagnosis	Sweden
	chronic	procedures, the necessity to	
	noninfectious	develop new methods for	

Corresponding Author:- Cahayag K.

Address:- School of Allied Health Sciences, Respiratory Therapy, San Pedro College, Davao City, Philippines, 8000.

Γ			
	respiratory	the monitoring of the	
	diseases	disease and adapt the	
		therapeutic strategies	
Sagaidak, S., Rowe, B. H., Ospina, M. B., &	Emergency	Services were redesigned to	Alberta,
Rosychuk, R. J. (2020)	department	address existing healthcare	Canada
	crowding	needs while also addressing	
	negatively	the burden of COVID-19-	
	influences	related illness.	
	outcomes for	Teluced Inness.	
	children		
	presenting with		
	· · ·		
	population-based		
	retrospective		
	cohort study.		
	Pediatric		
	Research.		
Turner, E., Johnson, E., Levin, K., Gingles, S.,	Multi-disciplinary	During the COVID-19	Scotland
Mackay, E., Roux, C., Milligan, M.,	community	pandemic, the Greater	
Mackie, M., Farrell, K., Murray, K., Adams, S.,	respiratory team	Glasgow & Clyde NHS	
Brand, J., Anderson, D., & Bayes, H. (2022).	management of	Trust Community	
• • • •	patients with	Respiratory Response Team	
	chronic	was developed to care for	
	respiratory illness	people with chronic	
	during the	respiratory conditions at	
	COVID-19	home. In this study, the	
	pandemic	effectiveness of the use of	
	Pulloonino	triage pathway, the usage of	
		remote consultations,	
		hospital admissions, and	
		patient's death were	
		examined.	
Halpin, D. M. G., Vogelmeier, C. F., & Agusti, A.	COVID-19 and	The probability of patients	USA
(2021)	COVID-19 and COPD: lessons		USA
(2021)		acquiring COVID or having	
	beyond the	poor outcomes is lower than	
	pandemic.	predicted, and certain	
		surprising discoveries may	
		result in major future	
		improvements in the	
		management of COPD,	
		despite the fact that the	
		pandemic has made the	
		diagnosis and routine	
		management of COPD	
		more challenging.	
Klouda, T., Pillarisetti, A., Xie, A., Kabra, S.,	Asthma	Reduced healthcare access	India
Saradhi, N., & Katwa, U. (2022).	Management in	and the socioeconomic	
	the Era of the	implications of the	
	COVID-19	pandemic may have an	
	Pandemic.	impact on how chronic	
		respiratory illnesses like	
		asthma are being treated,	
		particularly in areas with	
		little resources. With	
		0 0	
	1	disease monitoring and	

	1		,
		continued care during the pandemic, pediatric patients with chronic asthma need to be treated in accordance with internationally published recommendations. Children with acute asthma during the pandemic need to be carefully managed based on regional guidelines and	
Cathi S. Desislatoresia J. 7. 6 Tublic D. D.		utilizing stringent infection control procedures. When it comes to managing asthma during the pandemic, technology like telehealth and different tools like questionnaires and digital monitoring will be crucial.	
Sethi, S., Barjaktarevic, I. Z., & Tashkin, D. P. (2020).	The use of nebulized pharmacotherapies during the COVID-19 pandemic.	COVID-19 has brought attention to the necessity for precise and detailed instructions on the use of aerosol-generating techniques, such as nebulization, for the treatment of patients with respiratory illnesses, whether or not COVID-19 is present. The possibility of SARS-CoV-2 transmission via aerosolized respiratory droplets while treating COVID-19 patients with nebulizers has raised concerns despite the absence of supporting data. Metered-dose inhalers (MDIs) have become increasingly popular as an alternative to nebulized therapy as a result. However, some regions of the United States have insufficient MDI supplies.	USA
Chiner-Vives, E., Cordovilla-Pérez, R., de la Rosa- Carrillo, D., García-Clemente, M., Izquierdo- Alonso, J. L., Otero-Candelera, R., Pérez-de Llano, L., Sellares-Torres, J., & de Granda-Orive, J. I. (2022)	Short and Long- Term Impact of COVID-19 Infection on Previous Respiratory Diseases	COVID-19 infection can cause overall worsening of these previous respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, etc.	Spain
Liang, Y., Chang, C., Chen, Y., Dong, F., Zhang, L., & Sun, Y. (2020).	Symptoms, Management and	Before the outbreak, ICS/LABA (60.8%) and	China

	Healthcare	LAMA (57.5%) were the	
	Utilization of	most often used long-term	
	COPD Patients	maintenance medications,	
	During the	with 81.7% (125/153)	
	COVID-19	having them. The	
	Epidemic in	proportion of patients	
	Beijing.	receiving ICS/LABA	
	5 0	(53.6%) and LAMA	
		(56.9%) decreased	
		somewhat during the	
		epidemic, although 75.2%	
		(115/153) of patients	
		continued their	
		pharmaceutical treatment.	
		Only 6.5% (10/153) of	
		patients had to cut or stop	
		taking their drugs. During	
		the outbreak, the majority	
		of the patients had low	
		symptom burdens and CAT	
		scores under 10, or 76.5%	
		(117/153). Of 153	
		individuals, 45 (29.4%)	
		reported worsening	
		respiratory symptoms,	
		although only 15.6% (7/45)	
		sought medical attention in	
		hospitals. The remaining	
		patients (55.5%, 25/45)	
		expressed worries about	
		hospital cross-infection or	
		had minor symptoms that	
		they were able to manage	
		on their own (28.8%,	
		13/45).	
		During the COVID-19	
		outbreak in Beijing, most of	
		our COPD patients	
		· · · · · · · · · ·	
		maintained their long-term pharmacological therapy	
		and had mild-to-moderate	
		symptoms. Approximately,	
		30.0% of the patients had	
		exacerbation of respiratory	
		symptoms, however most of	
		them did not seek medical	
		care in the hospital owing to	
		worries about cross-	
		infection.	
Arabi, Y. M., Azoulay, E., Al-Dorzi, H. M., Phua,	How the COVID-	The COVID-19 pandemic	Saudi
J., Salluh, J., Binnie, A., Hodgson, C., Angus, D.	19 pandemic will	has brought disaster	Arabia
C., Cecconi, M., Du, B., Fowler, R., Gomersall, C.	change the future	preparedness's major	
D., Horby, P., Juffermans, N. P., Kesecioglu, J.,	of critical care	components into focus.	
Kleinpell, R. M., Machado, F. R., Martin, G. S.,		These include establishing	
Meyfroidt, G., Rhodes, A., Citerio, G. (2021).		strategic national or	
, , , , , , , , , , , , , , , , , , ,		regional stockpiles of	
	1	100 Storen Store	

		medications, medical supplies, and intensive care unit (ICU) equipment, as well as efficient supply networks and use guidelines. ICUs must be equipped to handle patient surges, and staffing plans must take demand changes into account. Principles for end-of-life care and ICU triage should be defined, put into practice, and updated. Daily workflow procedures should be reorganized to incorporate frequent communication with family members and remote connections with multidisciplinary healthcare workers. The pandemic has also illustrated the advantages of digital transformation and the worth of technologies for remote monitoring, including wireless monitoring. The pandemic has also demonstrated the importance of pre-existing epidemiological registries and flexible randomized controlled platform trials in generating timely, accurate data. The COVID-19 pandemic serves as a reminder that, in addition to our responsibility to care, we are dedicated to improving. We can better care for patients in the future if we address these challenges now.	
		generating timely, accurate data. The COVID-19 pandemic serves as a reminder that, in addition to our responsibility to care, we are dedicated to improving. We can better care for patients in the future if we address these	
Halpin, D. M. G., Criner, G. J., Papi, A., Singh, D., Anzueto, A., Martinez, F. J., Agusti, A. A., & Vogelmeier, C. F. (2021).	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease.	Spirometry should be used only when there is a high community incidence of COVID-19 to diagnose COPD and/or evaluate lung function status prior to interventional procedures or surgery. COPD patients should follow basic infection control techniques such as keeping a safe distance	USA

from others, washing their	
hands, and using a mask or	
other face covering.	
Recommended	
immunizations including	
the yearly flu shot should	
still be received by these	
patients.	
Notwithstanding the lack of	
data, inhaled	
corticosteroids, long-acting	
bronchodilators,	
roflumilast, or chronic	
macrolides should be used	
as indicated for stable	
COPD management.	
Systemic steroids and	
antibiotics should be	
delivered as directed in	
COPD exacerbations. In	
COPD exacerbations. In	
systemic steroids and	
antibiotics should be	
administered as prescribed.	
COVID-19 infection	
symptoms may be difficult	
to identify from underlying	
chronic symptoms or	
symptoms of an acute	
COPD exacerbation. If	
COVID-19 is suspected,	
testing for SARS-CoV-2	
should be considered.	
Emerging	
pharmacotherapeutic	
approaches such as	
emdesivir, dexamethasone,	
and anticoagulation are	
examples of	
pharmacotherapeutic	
techniques that should be	
utilized to treat individuals	
with moderate-to-severe	
COVID-19, including	
hospitalization and	
pneumonia. Managing acute	
1 2	
patients with COPD and	
severe acute respiratory	
distress syndrome should	
include adequate oxygen	
administration, prone	
positioning, noninvasive	
ventilation, and a protective	
lung strategy.	
Patients who experienced	
r anoms who experienced	

		1	
		moderate or asymptomatic	
		COVID-19 should be	
		monitored according to	
		standard COPD guidelines.	
		Patients who developed	
		moderate or worse COVID-	
		19 should have more	
		accurate and frequent	
		monitoring than the typical	
		COPD patients, with special	
		focus on the requirement	
		for oxygen therapy.	
Salvi, S., Dhar, R., Mahesh, P., Udwadia, Z., &	COPD	COPD patients should be	India
Behra, D. (2021). COPD Management	Management	encouraged to take more	
during the COVID-19 pandemic. Lung India,	during COVID 19	rigorous measures to reduce	
38(7), 80.	Pandemic	potential COVID-19	
https://doi.org/10.4103/lungindia.lungindia_685_20		exposures, and every effort	
		should be made to limit	
		their contact with suspected	
		or confirmed COVID-19	
		cases.	
		Staying at home, practicing	
		good hand hygiene, and	
		wearing a mask all help to	
		reduce the risk of	
		contracting COVID-19.	
		The GINA 2020 asthma	
		guidelines recommend	
		avoiding spirometry in	
		patients with	
		confirmed/suspected	
		COVID-19 and deferring	
		spirometry within	
		healthcare facilities unless	
		there is an urgent need.	
		Air conditioning should be	
		avoided whenever possible	
		because it reduces the air	
		exchange ratio. A thorough	
		medical history can aid in	
		distinguishing COPD from	
		other respiratory or	
		cardiovascular diseases.	

The COVID-19 pandemic put significant strain on healthcare systems around the world. Services were redesigned to address existing healthcare needs while also addressing the burden of COVID-19-related illness. The pandemic's impact on secondary care resources, as well as the increased risk of COVID-19 infection in patients with chronic health conditions, created a need for patients to be managed outside of the hospital setting, particularly those with pre-existing respiratory diseases^[1].

During the COVID-19 pandemic, in March 2020, the Greater Glasgow & Clyde NHS Trust Community Respiratory Response Team was created to handle patients with chronic respiratory disease at home. The team's goal was to avoid if not minimize hospitalization as much as possible by utilizing remote consultations. The outcomes of the triage pathway used, the use of remote consultations, hospital admissions, and mortality among patients managed by the team were examined in this observational study. The electronic health records of patients were reviewed

retrospectively. Within 28 days of referral, rates of emergency department attendance, hospital admission, and death were compared across triage pathways^[2].

Segmented linear regression was used to evaluate emergency admissions in Greater Glasgow and Clyde pre- and post-Community Respiratory Response Team implementation, using emergency admissions for chronic obstructive pulmonary disease in the rest of Scotland as a control and adjusting for all-cause emergency admissions. The triage category was related to hospital admission and death. The Community Respiratory Response Team was associated with a significant decrease in emergency admissions compared to the counterfactual if the service had not been in place, indicating a benefit in reducing secondary care pressures. During the COVID-19 pandemic, the Community, resulting in a reduction in secondary care pressures ^[2].

https://doi.org/10.1038/s41533-022-00290-y

Figure 1:- CRRT Triage pathway and patient outcomes by pathway

The majority of chronic respiratory disorders, with the exception of cystic fibrosis and asthma, are linked to worse outcomes and more severe COVID-19, although the underlying mechanisms are yet unknown. Patients with COVID-19 and chronic respiratory disorders receive similar therapeutic therapy as other patients, but in this population, the post-recovery course may be worse and be accompanied by the onset of pulmonary fibrosis, bronchiectasis, and pulmonary hypertension. The pandemic had a significant impact on our routine medical activities by restricting access to certain diagnosis procedures, necessitating the creation of new techniques for illness monitoring, and requiring the adaptation of therapeutic approaches. All of these modifications' potential long-term effects are currently unknowable ^[3].

Acute respiratory distress syndrome or pneumonia is more likely to occur in COVID-19 patients who have a history of cardiovascular problems, cancer, obesity, chronic lung disease, diabetes, or neurological disease. These patients also have the worst prognosis. Based on a person's immune system, age, and comorbidities, COVID-19 can have a variety of effects on the respiratory system and cause a range of illness severity. The signs of a disease can be slight, like a cough, shortness of breath, or fever, or serious, such as respiratory failure, shock, or multiple organ failure. Infection with COVID-19 can therefore result in a general worsening of these prior respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, etc. This review attempts to enlighten readers on the effects of the COVID-19 disease on pre-existing lung comorbidities ^[4]. https://pubmed.ncbi.nlm.nih.gov/35501222/#&gid=article-figures&pid=fig-1-uid-0

Figure 2: Health-care system changes in relation to COVID-19 pandemic in cystic fibrosis patients ^[4]

https://pubmed.ncbi.nlm.nih.gov/35501222/#&gid=article-figures&pid=fig-2-uid-1 Figure 3: Mind map of the impact of COVID-19 on pulmonary vascular diseases.

Connected by dashed lines, the evidences in relation to COVID-19 and pulmonary vascular diseases. Unconnected circles are thoughts of the COVID-19 pandemic. LMWH: low molecular weight heparin; PH/CTEPH: pulmonary hypertension and chronic thromboembolic pulmonary hypertension^[4].

Patients diagnosed with COPD are at a higher risk of contracting COVID-19, developing a more severe form of COVID-19 disease, and dying from it. COPD patients should be encouraged to take more rigorous measures to reduce potential COVID-19 exposures, and every effort should be made to limit their contact with suspected or confirmed COVID-19 cases. Staying at home, practicing good hand hygiene, and wearing a mask all help to reduce the risk of contracting COVID-19. It is critical to ensure that COPD is well managed through appropriate pharmacotherapy, vaccination (influenza and pneumococcal), and rehabilitation and that all precautions are taken to avoid the development of any acute exacerbation ^[5].

Spirometry is the gold standard diagnostic test for COPD and should be performed on all patients to confirm the diagnosis. However, because of the effort required to perform the test, it is an aerosol-generating procedure with a significantly increased risk of infection transmission to and from other patients and clinic/hospital staff. The GINA 2020 asthma guidelines recommend avoiding spirometry in patients with confirmed/suspected COVID-19 and deferring spirometry within healthcare facilities unless there is an urgent need ^[5].

Spirometry is an aerosol-producing procedure that should be avoided in all patients with confirmed or suspected COVID-19, especially in areas where community transmission of COVID-19 has already occurred. Although GOLD has not yet issued an advisory on the use of spirometry in COPD patients for diagnosis or management, it appears prudent to avoid this test until the pandemic is over ^[5].

A thorough medical history and a brief clinical examination will be required to diagnose COPD. Both the patient and the physician should wear a surgical or dependable cloth mask while taking the COPD patient's history. The patient should be encouraged not to shout or speak loudly. Before and after each patient, the physician should sanitize their hands with 70% alcohol disinfectant and wear gloves while examining the patient, which should be discarded immediately after the examination is completed. Patients should sit on a round steel chair that can be quickly disinfected with 1% sodium hypochlorite. The outpatient clinic should have adequate ventilation. Air conditioning should be avoided whenever possible because it reduces the air exchange ratio. A thorough medical history can aid in distinguishing COPD from other respiratory or cardiovascular diseases^[5].

Conclusion:-

The impact of the pandemic has been evidently felt by patients with COPD, asthma and other chronic respiratory disease in many aspect of their lives. The findings on the review show that the Covid-19 Pandemic highly affected the usual medical activities as a result of the limitations in the access to several diagnosis procedures as well as in managing respiratory related diseases. Thus, a need to modify and develop new methods of assessment, diagnostics and therapeutic strategies in the management of chronic respiratory diseases was highly emphasized. Caring for patients with chronic respiratory diseases and COVID-19 poses special challenges for health workers both brought about by the disease and working environment.

Acknowledgement:-

The world is a wonderful place, and the researcher wishes to thank the institution and the people who want to develop and mold us into better writers. With that, we would like to express our heartfelt gratitude to San Pedro College and the School of Allied Health Sciences, led by Dean Fatima May Tesoro, for providing us with this wonderful opportunity and the inspiration to turn these into a literature review. Internally, the experience is both challenging and rewarding.

Conflict Of Interest

The authors declare that they have no conflict of interest.

References:-

1. Sagaidak, S., Rowe, B. H., Ospina, M. B., & Rosychuk, R. J. (2020). Emergency department crowding negatively influences outcomes for children presenting with asthma: a population-based retrospective cohort study. Pediatric Research.

2. Turner, E., Johnson, E., Levin, K., Gingles, S., Mackay, E., Roux, C., Milligan, M., Mackie, M., Farrell, K., Murray, K., Adams, S., Brand, J., Anderson, D., & Bayes, H. (2022). Multi-disciplinary community respiratory team management of patients with chronic respiratory illness during the COVID-19 pandemic. Npj Primary Care Respiratory Medicine, 32(1). https://doi.org/10.1038/s41533-022-00290-y

Tiotiu, A., Chong Neto, H., Bikov, A., Kowal, K., Steiropoulos, P., Labor, M., Cherrez-Ojeda, I., 3. Badellino, H., Emelyanov, A., Garcia, R., & Guidos, G. (2021). Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases. Expert review of respiratory medicine, 15(8), 1035-1048. https://doi.org/10.1080/17476348.2021.19517074. Chiner-Vives, E., Cordovilla-Pérez, R., de la Rosa-Carrillo, D., García-Clemente, M., Izquierdo-Alonso, J. L., Otero-Candelera, R., Pérez-de Llano, L., Sellares-Torres, J., & de Granda-Orive, J. I. (2022). Short and Long-Term Impact of COVID-19 Infection on Previous Diseases. Respiratory Archivos de bronconeumologia, 58 Suppl 1. 39-50. https://doi.org/10.1016/j.arbres.2022.03.011

5. Salvi, S., Dhar, R., Mahesh, P., Udwadia, Z., & Behra, D. (2021). COPD Management during the COVID-19 pandemic. Lung India, 38(7), 80. https://doi.org/10.4103/lungindia.lungindia_685_20

6. Halpin, D. M. G., Criner, G. J., Papi, A., Singh, D., Anzueto, A., Martinez, F. J., Agusti, A. A., & Vogelmeier, C. F. (2021). Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary

Disease. American journal of respiratory and critical care medicine, 203(1), 24–36. https://doi.org/10.1164/rccm.202009-3533SO

7. Arabi, Y. M., Azoulay, E., Al-Dorzi, H. M., Phua, J., Salluh, J., Binnie, A., Hodgson, C., Angus, D. C., Cecconi, M., Du, B., Fowler, R., Gomersall, C. D., Horby, P., Juffermans, N. P., Kesecioglu, J., Kleinpell, R. M., Machado, F. R., Martin, G. S., Meyfroidt, G., Rhodes, A., ... Citerio, G. (2021). How the COVID-19 pandemic will change the future of critical care. Intensive care medicine, 47(3), 282–291. https://doi.org/10.1007/s00134-021-06352-y

8. Halpin, D. M. G., Vogelmeier, C. F., & Agusti, A. (2021). COVID-19 and COPD: lessons beyond the pandemic. American journal of physiology. Lung cellular and molecular physiology, 321(5), L978–L982. https://doi.org/10.1152/ajplung.00386.2021

9. Klouda, T., Pillarisetti, A., Xie, A., Kabra, S., Saradhi, N., & Katwa, U. (2022). Asthma Management in the Era of the COVID-19 Pandemic. Indian journal of pediatrics, 89(2), 163–168. https://doi.org/10.1007/s12098-021-03979-z

10. Sethi, S., Barjaktarevic, I. Z., & Tashkin, D. P. (2020). The use of nebulized pharmacotherapies during the COVID-19 pandemic. Therapeutic advances in respiratory disease, 14, 1753466620954366. https://doi.org/10.1177/1753466620954366

11. Liang, Y., Chang, C., Chen, Y., Dong, F., Zhang, L., & Sun, Y. (2020). Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing. International journal of chronic obstructive pulmonary disease, 15, 2487–2494. https://doi.org/10.2147/COPD.S270448

12. Chovanec K, Howard NR. Acute Care Management During a Pandemic. Prof Case Manag. 2021 Jan/Feb;26(1):11-18. doi: 10.1097/NCM.0000000000467. PMID: 33214506.